SH2B3 and precursor B-cell acute lymphoblastic leukemia: Co-absence of TP53 and LNK genes have been shown to initiate pre-B ALL that resembles Ph-like B-ALL with JAK/STAT/mTOR pathway activation and responds in vitro and in vivo to JAK inhibitor (Ruxolitinib) and the dual mTOR and PI3K inhibitor (BEZ235) [85].